ABCL: AbCellera Biologics, Inc.
About
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Current Value
$2.691 Year Return
Current Value
$2.691 Year Return
Key Details
Market Cap
$800.44M
P/E Ratio
-4.52
1Y Stock Return
-37.56%
1Y Revenue Growth
-34.59%
Dividend Yield
0.00%
Price to Book
0.7
Strategies that include ABCL
Stock's related to ABCL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LOVE | 53.34% | $513.90M | +78.25% | 0.00% |
| ADPT | 52.59% | $661.15M | +6.16% | 0.00% |
| BEAM | 52.54% | $2.09B | -9.52% | 0.00% |
| NTLA | 51.72% | $1.44B | -50.35% | 0.00% |
| TDOC | 51.59% | $1.54B | -47.22% | 0.00% |
| W | 51.14% | $5.11B | -15.44% | 0.00% |
| XRAY | 50.96% | $3.75B | -39.08% | 3.32% |
| BXC | 50.85% | $1.01B | +40.40% | 0.00% |
| CRL | 50.75% | $9.52B | -3.20% | 0.00% |
| ARVN | 50.70% | $1.49B | +4.04% | 0.00% |
| OPEN | 50.57% | $1.14B | -31.62% | 0.00% |
| OXM | 50.53% | $1.19B | -19.07% | 3.56% |
| ETD | 50.33% | $740.01M | +7.77% | 5.25% |
| MCFT | 50.28% | $344.65M | -0.29% | 0.00% |
| FATE | 50.21% | $248.29M | -11.02% | 0.00% |
| MCB | 50.12% | $708.25M | +74.29% | 0.00% |
| ZD | 50.08% | $2.37B | -14.73% | 0.00% |
| CWH | 49.98% | $1.36B | +5.90% | 2.22% |
| SPCE | 49.73% | $196.64M | -84.01% | 0.00% |
| JOBY | 49.43% | $4.84B | +13.24% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EG | 0.17% | $15.92B | -8.98% | 2.02% |
| LRN | 0.17% | $4.43B | +74.97% | 0.00% |
| RYAN | 0.20% | $8.81B | +55.63% | 0.62% |
| JNPR | 0.24% | $11.61B | +30.55% | 2.49% |
| LITB | 0.31% | $35.48M | -75.45% | 0.00% |
| VSTA | -0.47% | $204.94M | -39.33% | 0.00% |
| CB | 0.59% | $114.43B | +26.00% | 1.24% |
| K | 0.61% | $27.77B | +52.50% | 2.79% |
| HUSA | -0.62% | $16.69M | -11.56% | 0.00% |
| CL | -0.69% | $76.48B | +22.25% | 2.12% |
| RAPT | 0.92% | $37.41M | -92.14% | 0.00% |
| AFL | -0.96% | $61.74B | +35.69% | 1.35% |
| BACK | -0.96% | $1.76M | -32.90% | 0.00% |
| PRT | -1.01% | $48.72M | -16.56% | 10.33% |
| BAH | 1.12% | $17.62B | +9.13% | 1.47% |
| CARV | 1.14% | $8.48M | -8.79% | 0.00% |
| KR | 1.20% | $42.03B | +35.08% | 2.11% |
| TXO | -1.25% | $737.26M | -1.80% | 13.22% |
| CANG | 1.26% | $253.50M | +212.50% | 0.00% |
| FATBB | 1.27% | $81.94M | -12.91% | 11.69% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -23.09% | $78.15B | +35.51% | 0.42% |
| PGR | -20.62% | $149.10B | +57.29% | 0.45% |
| CHD | -18.54% | $27.18B | +19.50% | 1.03% |
| COR | -16.90% | $47.48B | +21.20% | 0.86% |
| ACGL | -16.06% | $36.00B | +16.84% | 0.00% |
| CAH | -14.81% | $28.64B | +12.14% | 1.70% |
| MNR | -14.75% | $1.66B | -10.71% | 15.90% |
| CYD | -13.45% | $364.46M | -2.94% | 4.26% |
| AJG | -13.16% | $64.17B | +17.51% | 0.80% |
| RSG | -12.70% | $66.05B | +31.79% | 1.04% |
| ABBV | -12.70% | $294.35B | +20.07% | 3.72% |
| WRB | -12.27% | $22.94B | +29.98% | 0.69% |
| RNR | -12.25% | $13.74B | +23.09% | 0.58% |
| WM | -12.25% | $87.92B | +27.58% | 1.34% |
| CBOE | -12.07% | $21.46B | +15.84% | 1.11% |
| MMC | -11.71% | $108.41B | +10.89% | 1.37% |
| AMED | -9.83% | $2.95B | -3.95% | 0.00% |
| MRK | -9.35% | $244.21B | -5.55% | 3.18% |
| PULM | -8.17% | $19.83M | +202.98% | 0.00% |
| BRO | -7.70% | $31.27B | +47.55% | 0.49% |
ETF's related to ABCL
News
Yahoo
VANCOUVER, British Columbia, November 07, 2024--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Yahoo
The analysts might have been a bit too bullish on AbCellera Biologics Inc. ( NASDAQ:ABCL ), given that the company fell...
Yahoo
AbCellera Biologics ( NASDAQ:ABCL ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.51m (down 1.4% from...
Yahoo
Q3 2024 Abcellera Biologics Inc Earnings Call
Yahoo
Despite a widened net loss, AbCellera Biologics Inc (ABCL) strengthens its pipeline and partnerships, maintaining robust liquidity for future growth.
Yahoo
ABCL earnings call for the period ending September 30, 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.